loader
Please Wait
Applying Filters...

Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Pradofloxacin, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Pradofloxacin

    APIs // Active Pharmaceutical Ingredients

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    PharmaCompass

    Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    2D Structure
    1. Also known as: Veraflox, 195532-12-8, Pradofloxacin [inn], 6o0t5e048i, 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
    Molecular Formula
    C21H21FN4O3
    Molecular Weight
    396.4  g/mol
    InChI Key
    LZLXHGFNOWILIY-APPDUMDISA-N
    FDA UNII
    6O0T5E048I
    Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH. It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
    2.1.2 InChI
    InChI=1S/C21H21FN4O3/c22-16-6-13-18(26(12-3-4-12)9-15(20(13)27)21(28)29)14(7-23)19(16)25-8-11-2-1-5-24-17(11)10-25/h6,9,11-12,17,24H,1-5,8,10H2,(H,28,29)/t11-,17+/m0/s1
    2.1.3 InChI Key
    LZLXHGFNOWILIY-APPDUMDISA-N
    2.1.4 Canonical SMILES
    C1CC2CN(CC2NC1)C3=C(C=C4C(=C3C#N)N(C=C(C4=O)C(=O)O)C5CC5)F
    2.1.5 Isomeric SMILES
    C1C[C@H]2CN(C[C@H]2NC1)C3=C(C=C4C(=C3C#N)N(C=C(C4=O)C(=O)O)C5CC5)F
    2.2 Other Identifiers
    2.2.1 UNII
    6O0T5E048I
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. Veraflox

    2. 195532-12-8

    3. Pradofloxacin [inn]

    4. 6o0t5e048i

    5. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid

    6. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydro-1h-pyrrolo[3,4-b]pyridin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

    7. Pudofloxacin

    8. Unii-6o0t5e048i

    9. Pradofloxacin [mi]

    10. Schembl150884

    11. Chembl1256815

    12. Dtxsid60173229

    13. Pradofloxacin [green Book]

    14. Ex-a5917

    15. Zinc3827732

    16. Db11453

    17. Pradofloxacin [ema Epar Veterinary]

    18. A937065

    19. Q15679498

    20. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-octahydro-6h-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

    21. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]-nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid

    22. 8-cyano-1-cyclopropyl-7-((1s,6s)-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3quinolinecarboxylic Acid

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 396.4 g/mol
    Molecular Formula C21H21FN4O3
    XLogP30.4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count3
    Exact Mass396.15976871 g/mol
    Monoisotopic Mass396.15976871 g/mol
    Topological Polar Surface Area96.7 Ų
    Heavy Atom Count29
    Formal Charge0
    Complexity803
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    * Dogs:

    Treatment of:

    - wound infections caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius);

    - superficial and deep pyoderma caused by susceptible strains of the Staphylococcus intermedius group (including S. pseudintermedius);

    - acute urinary-tract infections caused by susceptible strains of Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius);

    - as adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues caused by susceptible strains of anaerobic organisms, for example Porphyromonas spp. and Prevotella spp.

    * Cats:

    Treatment of acute infections of the upper respiratory tract caused by susceptible strains of Pasteurella multocida, Escherichia coli and the Staphylococcus intermedius group (including S. pseudintermedius).

    Dogs: , Infections of the skin and soft tissues, i. e. superficial and deep pyoderma and wound infections caused by Gram-positive organisms, typically Staphylococcus spp. and Streptococcus spp. , and Gram-negative organisms such as Escherichia coli, Pseudomonas spp. and Proteus spp. , Infections of the urinary tract caused by Gram-negative bacteria such as enterobacteriaceae, e. g. Escherichia coli, Enterobacter spp. , Klebsiella spp. and Proteus spp. , Pseudomonas spp. , and Gram-positive organisms, typically Staphylococcus spp. , Infections of the gingiva and periodontal tissues caused by anaerobic organisms, for example Porphyromonas spp. , Prevotella spp. ; Fusobacterium spp. , Eikenella spp. and capnophilic bacteria such as Capnocytophaga spp. , , Cats: , Infections of the respiratory tract caused by Gram-negative organisms such as Pasteurella spp. , Escherichia coli and Pseudomonas spp. , and Gram-positive organisms such as Streptococcus spp. and Staphylococcus spp. ,

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    QJ01MA97

    QJ01MA

    Post Enquiry
    POST ENQUIRY